AstraZeneca Pharma India Limited — Important, 29-05-2025: General Updates

AstraZeneca Pharma India received approval to market Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional lung cancer indication targeting locally advanced, unresectable NSCLC with specific EGFR mutations post platinum-based chemoradiation. This expansion enhances AstraZeneca’s presence in targeted oncology treatments and could drive higher sales once launched for the new indication.